Skip to content
Back to ASPE

Aspen Neuroscience, Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 17, 2025
Transactions
6
Purchases
6
Sales
0
Purchase value
$35.00M
Sale value
$0.00

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Peter A. ThompsonDirector · 10% owner
4
Filed Nov 4, 2026Period of report Nov 2, 20260000947871-26-000981
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseNov 2, 2026
Common StockF2F3F41,000,000$15.00$15.00M3,589,132IndirectSee footnotes
Filing footnotes · 4
  1. F1Pursuant to the Issuer's Amended and Restated Certificate of Incorporation, as amended, each share of Series Seed-2 Convertible Preferred Stock, Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock, and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible, at the option of the holder, at any time. In connection with the completion of the Issuer's initial public offering of its Common Stock, each share of Preferred Stock automatically converted on a 1-for-9.8821 basis into shares of Common Stock, for no additional consideration. Share numbers give effect to such conversion. The securities have no expiration date.
  2. F2Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.
  3. F3Securities held by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP") is the general partner of OPI VII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of OrbiMed GP. By virtue of such relationships, OrbiMed GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VII. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VII, except to the extent of its or his pecuniary interest therein if any.
  4. F4Each of the Reporting Person, OrbiMed Advisors, and OrbiMed GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, or OrbiMed GP is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
Open on SEC EDGAR
Advisors LLC OrbimedDirector · 10% owner
Capital GP VII LLC OrbiMedDirector · 10% owner
4
Filed Nov 4, 2026Period of report Nov 2, 20260000947871-26-000980
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseNov 2, 2026
Common StockF2F3F41,000,000$15.00$15.00M3,589,132IndirectSee footnotes
Filing footnotes · 4
  1. F1Pursuant to the Issuer's Amended and Restated Certificate of Incorporation, as amended, each share of Series Seed-2 Convertible Preferred Stock, Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock, and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible, at the option of the holder, at any time. In connection with the completion of the Issuer's initial public offering of its Common Stock, each share of Preferred Stock automatically converted on a 1-for-9.8821 basis into shares of Common Stock, for no additional consideration. Share numbers give effect to such conversion. The securities have no expiration date.
  2. F2Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.
  3. F3Securities held by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("OrbiMed GP") is the general partner of OPI VII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of OrbiMed GP. By virtue of such relationships, OrbiMed GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VII. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VII, except to the extent of its or his pecuniary interest therein if any.
  4. F4This report on Form 4 is jointly filed by OrbiMed Advisors and OrbiMed GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated Peter Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
Open on SEC EDGAR
ARCH Venture Fund X, L.P.10% owner
ARCH Venture Fund X Overage, L.P.10% owner
ARCH Venture Partners X, LLC10% owner
ARCH Venture Partners X, L.P.10% owner
ARCH Venture Partners X Overage, L.P.10% owner
Burow Kristina10% owner
Crandell Keith10% owner
Gillis Steven10% owner
Nelsen Robert10% owner
4
Filed Nov 2, 2026Period of report Nov 2, 20260001193125-26-444147
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseNov 2, 2026
Common StockF1F266,666$15.00$999.99K66,666Direct
PurchaseNov 2, 2026
Common StockF2F466,667$15.00$1.00M66,667Direct
PurchaseNov 2, 2026
Common StockF51,200,000$15.00$18.00M1,200,000IndirectSee Footnote
Filing footnotes · 5
  1. F1Securities held by ARCH Venture Fund X, L.P. ("ARCH X"). ARCH Venture Partners X, L.P. ("AVP X LP") is the sole general partner of ARCH X.
  2. F2ARCH Venture Partners X, LLC ("AVP X LLC") is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow, Steven Gillis, and Robert Nelsen (collectively, the "AVP X Committee Members") comprise the investment committee of AVP X LLC. AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. Each of AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members disclaims beneficial ownership except to the extent of any pecuniary interest therein.
  3. F3Each share of Series Seed Convertible Preferred Stock, Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock, Series B Convertible Preferred Stock, and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 1-for-9.8821 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.
  4. F4Securities held by ARCH Venture Fund X Overage, L.P. ("ARCH X Overage"). ARCH Venture Partners X Overage, L.P. ("AVP X Overage LP") is the sole general partner of ARCH X Overage.
  5. F5Shares were purchased by ARCH Venture Fund XIV, L.P. ("ARCH XIV"). The AVP X Investment Committee Members also are members of the investment committee for ARCH XIV.
Open on SEC EDGAR
ARCH Venture Fund XIV, L.P.10% owner
ARCH Venture Partners XIV, LLC10% owner
ARCH Venture Partners XIV, L.P.10% owner
Berns Paul L10% owner
4
Filed Nov 2, 2026Period of report Nov 2, 20260001193125-26-444141
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseNov 2, 2026
Common StockF1F21,200,000$15.00$18.00M1,200,000Direct
Filing footnotes · 2
  1. F1Securities held by ARCH Venture Fund XIV, L.P. ("ARCH XIV"). ARCH Venture Partners XIV, L.P. ("AVP XIV LP") is the sole general partner of ARCH XIV.
  2. F2ARCH Venture Partners XIV, LLC ("AVP XIV LLC") is the sole general partner of AVP XIV LP. Paul Berns, Kristina M. Burow, Keith Crandell, Steven Gillis and Robert Nelsen (collectively, the "AVP XIV LLC Committee Members") comprise the investment committee of AVP XIV LLC. Each of AVP XIV LP and AVP XIV LLC may be deemed to beneficially own the shares held by ARCH XIV, and each of the AVP XIV LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XIV. Each of AVP XIV LP, AVP XIV LLC and the AVP XIV LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.